title: Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
abstract: OBJECTIVE
  Social cognition captures affect recognition, social cue perception, "theory of mind," empathy, and attributional style. The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs).
  
  
  METHODS
  Eighty-four patients completed the Facial Expression Recognition Test, the Voice Emotion Recognition Test, the Short Recognition Memory Test for Faces, and the Reading the Mind in the Eyes Test. Patients also completed the Visual Object and Space Perception Test (VOSP) as a control task, which would not engage social cognition. The patients were compared with fifty healthy controls matched for age and gender.
  
  
  RESULTS
  There were no significant differences on social cognitive performance between the FGA- and SGA-treatment groups. Nor was olanzapine superior to clozapine, FGAs or both. However, patients treated with FGAs performed significantly worse on VOSP compared to both groups treated with SGAs, a 10% difference.
  
  
  CONCLUSIONS
  We cannot conclude that SGAs were associated with better social cognition than FGAs. However, there were small but significant advantages for SGAs in non-social visual processing function, as evaluated with the VOSP.
authors.affiliation: Department of Mental Health, Hull York Medical School, Grimsby, UK.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Kucharska-Pietura
authors.forename: Ann
authors.initials: A
authors.lastname: Mortimer
authors.forename: Aneta
authors.initials: A
authors.lastname: Tylec
authors.forename: Andrzej
authors.initials: A
authors.lastname: Czernikiewicz
mesh_terms: D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001364:Awareness / Q000187:drug effects*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D016022:Case-Control Studies; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D003463:Cues; D004192:Discrimination, Psychological / Q000187:drug effects; D004644:Emotions / Q000187:drug effects; D005149:Facial Expression; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D012160:Retina / Q000187:drug effects; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012919:Social Behavior; D012938:Social Perception; D013067:Speech Perception / Q000187:drug effects; D056345:Theory of Mind; D014796:Visual Perception / Q000187:drug effects*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010546:Perphenazine; D003024:Clozapine; D006220:Haloperidol; D000077152:Olanzapine